PNC Financial Services Group
MRNA icon

PNC Financial Services Group’s Moderna MRNA Stock Holding History

PNC Financial Services Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Buy
70,829
+946
+1% +$48.9K ﹤0.01% 766
2026
Q1 		$3.55M Buy
69,883
+20,422
+41% +$953K ﹤0.01% 809
2025
Q4 		$1.46M Sell
49,461
-3,687
-7% -$100K ﹤0.01% 1103
2025
Q3 		$1.37M Sell
53,148
-3,440
-6% -$96K ﹤0.01% 1102
2025
Q2 		$1.56M Buy
56,588
+18,701
+49% +$492K ﹤0.01% 1024
2025
Q1 		$1.07M Buy
37,887
+10,761
+40% +$382K ﹤0.01% 1137
2024
Q4 		$1.13M Sell
27,126
-6,873
-20% -$328K ﹤0.01% 1118
2024
Q3 		$2.27M Sell
33,999
-7,236
-18% -$664K ﹤0.01% 877
2024
Q2 		$4.9M Buy
41,235
+4,733
+13% +$599K ﹤0.01% 652
2024
Q1 		$3.89M Buy
36,502
+9,612
+36% +$969K ﹤0.01% 714
2023
Q4 		$2.67M Sell
26,890
-809
-3% -$68K ﹤0.01% 794
2023
Q3 		$2.86M Sell
27,699
-2,210
-7% -$247K ﹤0.01% 757
2023
Q2 		$3.63M Buy
29,909
+244
+0.8% +$32.5K ﹤0.01% 723
2023
Q1 		$4.56M Sell
29,665
-9,845
-25% -$1.62M ﹤0.01% 660
2022
Q4 		$7.1M Buy
39,510
+48
+0.1% +$7.85K 0.01% 549
2022
Q3 		$4.67M Buy
39,462
+10,526
+36% +$1.6M ﹤0.01% 629
2022
Q2 		$4.13M Buy
28,936
+4,807
+20% +$687K ﹤0.01% 683
2022
Q1 		$4.16M Buy
24,129
+4,122
+21% +$694K ﹤0.01% 720
2021
Q4 		$5.08M Sell
20,007
-3,706
-16% -$1.08M ﹤0.01% 699
2021
Q3 		$9.13M Buy
23,713
+7,943
+50% +$2.93M 0.01% 519
2021
Q2 		$3.71M Buy
15,770
+874
+6% +$156K ﹤0.01% 736
2021
Q1 		$1.95M Sell
14,896
-200
-1% -$29K ﹤0.01% 890
2020
Q4 		$1.58M Buy
15,096
+3,442
+30% +$348K ﹤0.01% 938
2020
Q3 		$826K Buy
11,654
+699
+6% +$48.7K ﹤0.01% 1130
2020
Q2 		$703K Buy
10,955
+6,727
+159% +$368K ﹤0.01% 1195
2020
Q1 		$127K Buy
4,228
+71
+2% +$1.63K ﹤0.01% 2078
2019
Q4 		$81K Buy
4,157
+1,752
+73% +$31.1K ﹤0.01% 2610
2019
Q3 		$38K Buy
2,405
+192
+9% +$2.84K ﹤0.01% 3058
2019
Q2 		$31K Buy
+2,213
New +$47.5K ﹤0.01% 3167

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

PNC Financial Services Group's MRNA Position: Q2 2026 in Review

PNC Financial Services Group increased its Moderna (MRNA) stake by 1.4% in Q2 2026, buying an estimated $48.9K and bringing the position to 70,829 shares worth $4.96M. The position accounts for ﹤0.01% of the portfolio, ranked #766.

PNC Financial Services Group first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $9.13M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • PNC Financial Services Group held 70,829 shares of Moderna worth $4.96M as of Q2 2026.
  • PNC Financial Services Group bought 946 Moderna shares in Q2 2026, an estimated $48.9K.
  • Moderna made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #766 holding.
  • PNC Financial Services Group first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • PNC Financial Services Group's Moderna position peaked at $9.13M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.